Joshua Liang
Directeur Général chez CLOVER BIOPHARMACEUTICALS, LTD.
Fortune : 903 810 $ au 30/04/2024
Profil
Joshua Liang is currently the Chief Executive Officer & Director at Sichuan Clover Biopharmaceuticals, Inc. He is also the Chief Executive Officer & Executive Director at Clover Biopharmaceuticals Ltd., Clover Biopharmaceuticals USA, Inc., Clover Biopharmaceuticals Aus Pty Ltd., and Clover Biopharmaceutical Beijing Co. Ltd.
Additionally, he holds the position of General Manager & Director at Clover Biopharmaceuticals Hong Kong Ltd.
and General Manager & Executive Director at Clover Biopharmaceuticals Shanghai Co. Ltd.
Mr. Liang started his career as the General Manager & Director at Zhejiang Clover Biopharmaceutical, Inc. He completed his undergraduate degree at the University of Pennsylvania and also studied at The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/04/2024 | 20 489 909 ( 1,58% ) | 903 810 $ | 30/04/2024 |
Postes actifs de Joshua Liang
| Sociétés | Poste | Début |
|---|---|---|
| CLOVER BIOPHARMACEUTICALS, LTD. | Directeur Général | 25/12/2020 |
Sichuan Clover Biopharmaceuticals, Inc
 Sichuan Clover Biopharmaceuticals, Inc Pharmaceuticals: MajorHealth Technology Sichuan Clover Biopharmaceuticals, Inc is a clinical-stage biotechnology company based in Chengdu, China. Clover Biopharmaceuticals' mission is to leverage their trimer-tag technology and in-house manufacturing capabilities to develop and deliver innovative and affordable medical solutions. The Chinese company is committed to partnering with leading healthcare organizations to advance their breakthrough pipeline programs and deliver them to patients. The company's pipeline includes many vaccine and therapeutic candidates for the treatment of infectious disease, cancer, and autoimmune disease, created using trimer-tag platform technology. The company was founded in 2007 by Peng Liang, and Joshua Liang has been the CEO of the company since 2016. | Directeur Général | 01/06/2020 |
| Zhejiang Clover Biopharmaceutical, Inc. | Directeur Général | 01/08/2016 |
| Clover Biopharmaceutical Beijing Co. Ltd. | Directeur Général | 01/08/2020 |
| Clover Biopharmaceuticals Shanghai Co. Ltd. | Directeur Général | 01/02/2021 |
| Clover Biopharmaceuticals USA, Inc. | Directeur Général | 01/04/2020 |
| Clover Biopharmaceuticals Aus Pty Ltd. | Directeur Général | 01/12/2020 |
| Clover Biopharmaceuticals Hong Kong Ltd. | Directeur/Membre du Conseil | 01/12/2020 |
Formation de Joshua Liang
| University of Pennsylvania | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CLOVER BIOPHARMACEUTICALS, LTD. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Sichuan Clover Biopharmaceuticals, Inc
Sichuan Clover Biopharmaceuticals, Inc Pharmaceuticals: MajorHealth Technology Sichuan Clover Biopharmaceuticals, Inc is a clinical-stage biotechnology company based in Chengdu, China. Clover Biopharmaceuticals' mission is to leverage their trimer-tag technology and in-house manufacturing capabilities to develop and deliver innovative and affordable medical solutions. The Chinese company is committed to partnering with leading healthcare organizations to advance their breakthrough pipeline programs and deliver them to patients. The company's pipeline includes many vaccine and therapeutic candidates for the treatment of infectious disease, cancer, and autoimmune disease, created using trimer-tag platform technology. The company was founded in 2007 by Peng Liang, and Joshua Liang has been the CEO of the company since 2016. | Health Technology |
| Zhejiang Clover Biopharmaceutical, Inc. | |
| Clover Biopharmaceutical Beijing Co. Ltd. | |
| Clover Biopharmaceuticals Shanghai Co. Ltd. | |
| Clover Biopharmaceuticals USA, Inc. | |
| Clover Biopharmaceuticals Aus Pty Ltd. | |
| Clover Biopharmaceuticals Hong Kong Ltd. |